 After the market close on Thursday, Guardant Health Inc NASDAQ: GH reported Q2 revenues increased 39 YY to 92.1 million, beating the consensus of 84.61 million. Guardants oncology testing revenue grew 42 to 72.6 million, driven primarily by a 54 increase in clinical testing revenue. 